Key facts
- It has raised $10K; the latest was Early Stage VC in Mar 2025.
- Notable investors include Creative Destruction Lab, Verve Ventures, Modi Ventures, Enterprise Hub - Royal Academy of Engineering, ICURe.
- Status: Privately Held (backing).
- ·The complete investor list — 5 names
- ·Watchlist + deal alerts for Case45
- ·The full record, as it builds
Funding rounds
No funding rounds for Case45 are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Case45
Developer of novel pan-cancer precision biomarkers designed to prognosticate and tailor therapies for patients. The company offers a generalizable AI engine that integrates various medical data with tissue images by assessing immune responses within tumor ecosystems, enabling doctors to stay ahead of cancer, prescribe optimized treatments, and ultimately defeat it.
- Sector
- Healthcare
- HQ
- London, United Kingdom
- Founded
- 2022
- Employees
- 3
- Website
- case45.com/
- Ownership
- Privately Held (backing)
Case45 doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Case45 shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Case45 in its N-PORT filings yet. We sweep new filings monthly.